Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
Want to see HK:2696 full AI Analyst Report?
2696 Stock Chart & Stats
HK$84.45
HK$0.05(0.21%)
At close: 4:00 PM EST
HK$84.45
HK$0.05(0.21%)
Day’s Range― - ―
52-Week RangeHK$39.70 - HK$92.00
Previous CloseN/A
Volume849.10K
Average Volume (3M)1.53M
Market Cap
HK$38.32B
Enterprise ValueHK$36.22B
Total Cash (Recent Filing)HK$972.50M
Total Debt (Recent Filing)HK$3.67B
Price to Earnings (P/E)―
Beta0.27
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding346,074,400
10 Day Avg. Volume1,665,497
30 Day Avg. Volume1,532,406
Financial Highlights & Ratios
PEG Ratio51.24
Price to Book (P/B)7.08
Price to Sales (P/S)4.21
P/FCF Ratio32.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$99.12Price Target Upside17.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Sustained ProfitabilityConsistent high gross margins and multi-year profitability indicate durable product economics and effective cost of goods control. For a biologics company this underpins long-term cash generation, supports reinvestment in R&D and manufacturing, and reflects successful commercialization of core products.
Improving Balance Sheet / DeleveragingMarked reduction in leverage materially improves financial flexibility and lowers refinancing risk over the medium term. Stronger equity and lower debt increase resilience to development setbacks and provide capacity for selective investment or partnership funding without immediate financing pressure.
Consistent Positive Cash GenerationSustained operating cash flow and recent positive free cash flow demonstrate the business converts earnings into cash, enabling self-funded R&D and manufacturing scale. This reduces dependency on external capital and supports durable execution of commercialization and capacity expansion plans.
Bears Say
Residual Leverage And Historical VolatilityDespite improvement, meaningful and historically volatile leverage leaves the company sensitive to execution risks and interest-cost changes. That structural vulnerability can constrain strategic flexibility, increase refinancing risk during downturns, and amplify impacts of development delays on cash flow.
2025 Margin CompressionObserved margin erosion in 2025 suggests rising costs or pricing/mix pressures that could persist. If structural (higher SG&A, R&D or pricing competition), compressed margins erode cash generation and limit the funding available for sustained pipeline investment and manufacturing capacity.
Uneven Cash Conversion & Past Negative FCF PeriodsVolatile cash conversion and episodes of negative free cash flow signal that funding needs can spike during investment cycles. This structural unevenness raises the likelihood of episodic external financing, which could dilute shareholders or increase leverage when the company scales new products or capacity.
Shanghai Henlius Biotech, Inc. Class H News
2696 FAQ
What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$39.70 and its highest was HK$92.00 in the past 12 months.
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$38.32B.
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Currently, no data Available
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Undervalued.
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
Shanghai Henlius Biotech, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
Shanghai Henlius Biotech, Inc. Class H has 346,074,400 shares outstanding.
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2696
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Henlius Biotech, Inc. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.03%
12-Months-Change
Fundamentals
Return on Equity
25.67%
Trailing 12-Months
Asset Growth
18.00%
Trailing 12-Months
Company Description
Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
2696 Stock 12 Month Forecast
Average Price Target
HK$99.12
▲(17.37% Upside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---